No significant differences were found in acute cardiovascular events, acute DVT/PE, mechanical ventilator support, and mortality rate between hospitalized COVID-19 patients who were taking aspirin compared to those not taking aspirin. However, larger studies are required to confirm our findings.
Keyphrases
- cardiovascular events
- coronary artery disease
- coronavirus disease
- cardiovascular disease
- sars cov
- liver failure
- low dose
- end stage renal disease
- respiratory failure
- ejection fraction
- newly diagnosed
- aortic dissection
- prognostic factors
- peritoneal dialysis
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- respiratory syndrome coronavirus
- extracorporeal membrane oxygenation
- case control